- Home
- FORA vs CTSO Comparison
FORA vs CTSO Comparison
Compare FORA & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FORA | CTSO |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 45.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FORA | CTSO |
|---|---|---|
| Price | $2.14 | $0.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 36.0K | ★ 114.9K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $28,106,911.00 | ★ $36,979,520.00 |
| Revenue This Year | $47.82 | $9.51 |
| Revenue Next Year | $10.11 | $24.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.47 | 23.89 |
| 52 Week Low | $1.64 | $0.60 |
| 52 Week High | $4.03 | $1.61 |
Technical Indicators
Market Signals| Indicator | FORA | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 43.59 |
| Support Level | $2.11 | $0.66 |
| Resistance Level | $2.20 | $0.76 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 50.00 | 24.33 |
Price Performance
Historical ComparisonAbout FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.